Target Health Inc., is a full-service e*CRO committed to improving the way companies run clinical trials. We have successfully used Target e*CRF® in over 100 clinical trails. We leverage our industry knowledge, experience, technology and connectivity to streamline how companies run studies.

With superior, consistent performance and a diverse team of experts, we work to the highest standards of ethical conduct and integrity. As noted by a recent client, “It took a week from LPLV to locked database. We could not have submitted our data and gotten approval so fast if it was not for Target e*CRF ® and your team's expertise.”

Why Target Health?

• Over 100 EDC trials, worldwide
• Integrated processes, people, and technology
• Consistently meet patient enrollment
• One week from last patient visit(LPLV) to database lock
• Proven track record of NDA and PMA approvals
• Regulatory expertise [represent over 20 clients at FDA]
• Flawless FDA & client audits

Latest News

Regulatory Meeting at Health Canada

Dr. Glen Park, Sr. Director, Clinical and Regulatory Affairs presided at a very successful, highly interactive Pre-CTA meeting in Ottawa. The weather was beautiful and the view of the Ottawa River from the meeting room was breathtaking. The project is already ongoing in Israel, South Africa, and the US and will be shortly starting in Europe. Target Health is monitoring in the US and Canada, and performing 1) the global EDC trial, 2) data management, 3) biostatistics and 4) medical writing. We will also submit the NDA at the completion of the program

Life on EDC Street - By Deborah Borfitz (Bio-IT World Oct. 10, 2007)

As quoted by Chip Kalfaian , director of the life science solutions division of Cranford, NJ-based Paragon Solutions, “Although consolidation is likely, including acquisitions by contract review organizations (CROs), smaller EDC vendors like Target Health (New York, NY) continue to pop up in the market with dynamic EDC tools.”

Dr. Mitchel Presents at RAPS (Regulatory Affairs Professionals Society)

On September 25, 2007, Dr. Jules Mitchel of Target Health, together with Dr. Evan B. Siegel, of Ground Zero Pharmaceuticals Inc., and Dr. Miriam Provost, of M Squared Associates Inc.and former Deputy Director of the Office of Device Evaluation at CDRH (Device Division at FDA) presented talks at RAPS on the Differences in Clinical Trials for Drugs, Biologics and Devices. Dr. Mitchel featured his experience with 2 approved PMA products, one a drug/device combination and the second, a surgical cardiology device tested in the newborn. Drs Sigel and Provost shared their broad experience in drugs, biologics and drug development. Click here for the slide presentation.

arGentis Pharmaceuticals Selected Target Health As Its CRO Partner For Their Upcoming Clinical Trials

arGentis Pharmaceuticals, LLC has selected Target Health, Inc. as its Clinical Research Organization (CRO) partner for their upcoming clinical trials. With clinical trial costs increasing dramatically, it has been demonstrated that the selection of a quality CRO provides cost saving opportunities for their drug sponsors. Utilizing Target Health’s global expertise across multiple therapeutic categories will allow arGentis to expand development capacity without requiring an increase in staff or facilities. Click here for the press release.